# The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II

Study · id `cardio:ct-nct02281838` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02281838](<https://clinicaltrials.gov/study/NCT02281838>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02281838

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: High blood pressure; Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.

## Technical summary

Registry record NCT02281838. Randomized; no masking; primary purpose treatment. Start 2011-08-01 (actual); primary completion 2021-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 142 participants (enrolled count; ClinicalTrials.gov record NCT02281838, source copy `cardio:ctgov-nct02281838-2024-11-06`, retrieved 2026-10-26)
- Started: 2011-08-01 (actual) (ClinicalTrials.gov record NCT02281838, source copy `cardio:ctgov-nct02281838-2024-11-06`, retrieved 2026-10-26)
- Primary completion: 2021-11 (actual) (ClinicalTrials.gov record NCT02281838, source copy `cardio:ctgov-nct02281838-2024-11-06`, retrieved 2026-10-26)
- Completion: 2021-12 (actual) (ClinicalTrials.gov record NCT02281838, source copy `cardio:ctgov-nct02281838-2024-11-06`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02281838, source copy `cardio:ctgov-nct02281838-2024-11-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02281838-2024-11-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II
- Acronym: ICH-ADAPT II
- Condition: Intracerebral Hemorrhage
- Intervention (Drug): labetalol/hydralazine/enalapril
- Lead sponsor: University of Alberta
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: University of Alberta (`cardio:org-university-of-alberta`)

## Provenance

Content hash: b46f118378a3cc420b0cfc138706a00d241608b44e0b775e01b202248362dac8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
